Phathom Pharmaceuticals, Inc. Net Debt

Net Debt of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Debt growth rates and interactive chart. Net debt is the sum of all interest-bearing debt (short-term and long-term) minus cash and short-term investments. A positive number indicates the company's total debt exceeds its cash and short-term investments balances, while a negative number means the company has more cash than its total debt. This figure is also used in Enterprise value calculation.


Highlights and Quick Summary

  • Net Debt for the quarter ending September 29, 2021 was $-135 Million (a -15.97% decrease compared to previous quarter)
  • Year-over-year quarterly Net Debt decreased by -43.58%
  • Annual Net Debt for 2020 was $-238 Million (a 8.3% increase from previous year)
  • Annual Net Debt for 2019 was $-220 Million (a -20659.48% decrease from previous year)
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Debt of Phathom Pharmaceuticals, Inc.

Most recent Net Debtof PHAT including historical data for past 10 years.

Interactive Chart of Net Debt of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Net Debt for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-134.55 $-160.13 $-188.68
2020 $-238.48 $-177.67 $-201.01 $-210.61 $-238.48
2019 $-220.83 $43.36 $-220.19
2018 $1.07 $1.07

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.